Biomarker Discovery of Pancreatic and Gastrointestinal Cancer by 2DICAL: 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry
Figure 3
Discovery and validation of Complement Component 9 as a colorectal cancer biomarker (partially changed from [12]). (a) 2DICAL images with coordinates m/z versus RT. The intensity of the peak of 622 m/z and RT of 56.8 min (indicated by arrows) are clearly different in the plasma samples from healthy controls (left) and colorectal cancer patients (right). (b) Western blot of Complement Component 9 and the loading control α2-macroglobulin. (c) Large-scale RPPA validation of the plasma level of Complement Component 9 using hundreds of clinical samples.
